Navigation Links
Statement by Ronald L. Stotish, Ph.D., President and CEO of AquaBounty Technologies

WALTHAM, Mass., June 16, 2011 /PRNewswire-USNewswire/ -- Background: The U.S. House of Representatives yesterday passed an amendment to H.R. 2112, the House agricultural appropriations bill, co-sponsored by Rep. Don Young (R-AK) and Rep. Lynn Woolsey (D-CA) to prohibit funding for U.S. Food and Drug Administration approval of salmon grown from AquaBounty Technologie's AquAdvantage salmon eggs.  The amendment was voted on by fewer than ten of the total 435 House members.

The U.S. FDA has conducted a rigorous 15-year review of thousands of pages of data and has concluded that these fish are exactly the same as any other Atlantic salmon and, therefore, are safe for consumption.  In addition, the fish will be sterile and required to be grown in self-contained inland tanks, so pose no threat to the environment.  Finally, the United Nations reports that the wild caught fisheries are severely stressed, with  major food species potentially extinct by 2050, yet the demand for fish protein is exploding worldwide. America currently imports more than 97% of the Atlantic salmon consumed here, so Young et al are really supporting foreign salmon producers.


"This outrageous action is wrong on the facts, wrong on the process and wrong on the policy.  A handful of representatives have chosen to subvert the FDA's rigorous 15-year plus process. It completely ignores the results of a rigorous scientific review. This sort of political gamesmanship undermines the science-based system that protects the nation's health and safety. It is astonishing that Young and a few colleagues would try to game the system in this way."

"Whether or not you support this transgenic salmon, we should all agree these types of shenanigans have no place in a complex scientific debate.  These actions threaten the fundamental basis of a science-based regulatory process. Americans deserve better from their elected representatives."

SOURCE AquaBounty Technologies
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Resverlogix Issues a Management Statement
2. Extraordinary General Meetings Statement - XTL Notifies NASDAQ of Compliance with Marketplace Rule 4350(d)(2)
3. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
4. Sinovac Releases Statement on Healive Vaccine Suspension
5. CV Therapeutics Statement on Unsolicited Proposal From Astellas
6. GPhA Statement on the Introduction of the Bipartisan Biogenerics Consensus Bill: Promoting Innovation and Access to Life-Saving Medicine Act
7. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
8. Extraordinary General Meetings Statement -- XTL Also Announces Board and Management Changes
9. Advanced Life Sciences Announces Filing of Shelf Registration Statement
10. Amylin Issues Statement in Response to Carl Icahn
11. DuPont Statement on Obama Administration Biofuels Interagency Working Group
Post Your Comments:
(Date:11/25/2015)... Studies reveal the differences in species of ... way for more effective treatment for one of the most ... --> --> Gum disease is ... yet relatively little was understood about the bacteria associated with ... by researchers from the WALTHAM Centre for Pet Nutrition together ...
(Date:11/25/2015)... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) ... chat discussion at the Piper Jaffray 27th Annual Healthcare ... discussion is scheduled for Wednesday, December 2, at 8:00 ... replay will be available for 14 days after the ... NormartVP, Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
(Date:11/24/2015)... -- Cepheid (NASDAQ: CPHD ) today announced that ... and invited investors to participate via webcast. ... 1, 2015 at 11.00 a.m. Eastern Time --> ... 1, 2015 at 11.00 a.m. Eastern Time --> ... NY      Tuesday, December 1, 2015 at 11.00 ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
Breaking Biology Technology:
(Date:11/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), the ... entry into the automotive market with a comprehensive and ... of consumer electronics human interface innovation. Synaptics, industry-leading touch ... the automotive industry and will be implemented in numerous ... , Japan , and ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
Breaking Biology News(10 mins):